NEW YORK, NY--(Marketwire - May 17, 2010) - Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview® (EIO®) on Peregrine Pharmaceuticals, Inc. (
Peregrine Pharmaceuticals, Inc. ("Peregrine" or "the Company") is a clinical-stage biopharmaceutical company focused on the development of monoclonal antibody (MAb)-based therapeutics for oncology and viral diseases. Peregrine's proprietary MAbs have demonstrated broad-spectrum potential in cancer and viral disease and target a range of diseased cells, including cells lining the blood vessels that feed tumors, cells that have been infected with an enveloped virus, and the dead or dying cells (necrosis) found at the core of solid tumors.
Peregrine is advancing its clinical programs for bavituximab, a phosphatidylserine (PS)-targeting MAb to treat certain cancers and viral infections, and Cotara®, a novel brain cancer therapy. Bavituximab, in combination with chemotherapy, is in a Phase II trial for non-small cell lung cancer (NSCLC) and two Phase II trials for advanced breast cancer. Bavituximab is also in a Phase I trial in patients co-infected with hepatitis C virus (HCV) and HIV. Cotara is in a Phase II study in patients with relapsed glioblastoma multiforme (GBM), an aggressive and often fatal brain cancer. This trial has recently been expanded to include U.S. sites.
Peregrine has two sources of revenue: (1) its subsidiary Avid Bioservices®, Inc., which provides commercial biomanufacturing services for both Peregrine and outside customers; and (2) a government contract valued at up to $44 million for five years.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small- and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview® (EIO®), is free of investment ratings, target prices, and forward-looking financial models. The EIO® presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO® details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, West Palm Beach, Montréal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of fifty-four thousand dollars for its services in creating this report, for updates, and for printing costs.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with the SEC.
These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.
Jeffrey J. Kraws/Karen B. Goldfarb
Crystal Research Associates, LLC
P: (609) 306-2274
F: (609) 395-9339